VX-509 (Decernotinib) Is a Potent and Selective Janus Kinase 3 Inhibitor That Attenuates Inflammation in Animal Models of Autoimmune Disease
Article in Journal of Pharmacology and Experimental Therapeutics (March 2015)
The most recent citing publications are shown below. View all 2 publications that cite this research output on Dimensions.
Article in Journal of Pharmacology and Experimental Therapeutics (March 2015)
Article in Scientific Reports (October 2014)